The Opportunity
 The Process
   Drug Development    Regulatory Approval
Home About Us Technology Contact Us
Many potentially disruptive biomaterial innovations never reach the market because the companies capable of commercializing them are unwilling to take risks before the inventive idea has reached a fairly advanced stage of development. PharMedica provides the crucial missing link: Bringing new biomaterials out of the lab and developing them to commercialization.


Stage I: Fill Pipeline
Screen biomaterial candidates from academic and research institutions in Israel and around the world Perform due diligence to include testing in Pharmedica GLP-compliant lab facilities
Stage II: Preclinical Evaluation
Carry out in vivo and in vitro safety and efficacy testing over 1 year,  carry out bench-scale production, and develop initial regulatory and reimbursement strategy
Stage III: Phase I/II Clinicals
Carry out clinical (human) trials over 2 to 3 years, first; early-stage formulation and pilot-scale-production at outsourced GMP facilities
Stage IV: Go to Market
Develop strategic partnerships or form joint ventures with large life science companies to complete Phase III clinical trials, regulatory approvals, and marketing

  PharMedica Ltd. Tel: +972.4.834.2155 Fax: +972.4.834.1233